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Abstract
In this review, we compared the potential of mesenchymal stem cells derived from bone marrow, adipose tissue and 
umbilical cord as suitable sources for regeneration of inner ear hair cells and auditory neurons. Our intensive literature 
search indicates that stem cells in some of adult mammalian tissues, such as bone marrow, can generate new cells under 
physiological and pathological conditions. Among various types of stem cells, bone marrow-derived mesenchymal 
stem cells are one of the most promising candidates for cell replacement therapy. Mesenchymal stem cells have been 
reported to invade the damaged area, contribute to the structural reorganization of the damaged cochlea and improve 
incomplete hearing recovery. We suggest that bone marrow-derived mesenchymal stem cells would be more beneficial 
than other mesenchymal stem cells.
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INTRODUCTION
Hearing loss is one of the most prevalent disabilities. 
Approximately over 5% of the world’s population-360 
million people-suffer from disabling hearing loss (328 
million adults and 32 million children). Hair cells and spiral 
ganglion neurons are usually damaged in most people 
with hearing loss. Hearing loss is also the most common 
sensory disorder in humans. Recent developments in 
stem cell technology have offered new opportunities to 
treat deafness. The present review seeks to investigate 
different types of mesenchymal stem cells (MSCs) 
(derived from bone marrow, adipose tissue, and umbilical 
cord) as potential sources for regeneration of inner ear 
cells. Since cells with stem/progenitor properties appear 
to be no longer present in the mammalian cochlea three 
weeks after birth1,2, this work mainly focuses on the 
utilization of exogenous cells and their differentiation 
into the missing auditory cells. A wide range of stem/
multipotent progenitor cells have been tested for their 
capability to differentiate toward inner ear sensory cells 
in vitro and in vivo3-5. Several groups have shown the 
possibility of mouse embryonic stem cells (mESCs) to 
differentiate into hair cells6,7 and auditory neuron-like 
cells8-11. Differentiation methods to induce hair cell-like 
cells from ESCs or induced pluripotent stem cells (iPSCs) 
seem to be effective but require great proficiency6,7. 
The beneficial phenotypic plasticity of ESCs is always 
challenged by ethical questions on derivation and use 
of these human cells and other concerns such as the 
likelihood of immune reactions and tumor formation12-14. 
Alternative sources are mesenchymal tissues. 
Indeed, inner ear hair cells have been successfully 
generated in vitro by a mesenchymal-to-epithelial 
transition15. Considering the potential of MSCs to 
differentiate into neural type cells, these cells would be 
good candidates for regenerative cell-based therapies16-20. 
Multipotent MSCs are capable to restore damaged 
mesenchyme via differentiation into mature cells of 
bone, cartilage, muscle, fat or fibrous tissues. MSCs 
exhibit remarkable self-renewal capacity and the ability 
to differentiate not only into osteoblasts, chondrocytes, 
adipocytes, myocytes, but even also into neurons in vitro 
and in vivo21 and therefore, MSCs have been successfully 
used in otorhinolaryngology. MSCs produce bioactive 
anti-inflammatory agents and support regeneration of 
injured tissues22-25. Among the various types of stem cells, 
bone marrow-derived MSCs (BMSCs) are one of the most 
promising candidates for cell replacement therapy.
Biological characteristics of MSCs
MSCs are characterized with self-healing, self-
renewing, highly proliferative, differentiation potential, 
and adherent growing features. Despite expression of 
CD105, CD73 and CD90, these cells do not express CD45, 
CD34, CD14, CD19 and HLA-DR surface molecules. 
MSCs can be induced to differentiate toward bone cells, 
fat cells, cardiac muscle cells, nerve cells and epithelial 
cells transformation26,27. And the resulting cells must be 
characterized via evaluation of above mentioned markers.
Growth factors to induce BMSCs differentiation for 
regeneration of inner ear cells
In the presence of specific growth factors such 
as Sonic hedgehog and retinoic acid, BMSCs have the 
capacity to differentiate into sensory neurons27-29. In a 
recent study on BMSCs, the inner ear specific genes such 
as NF-M, neurog1, gluR4, neuroD, calretinin, neuN, tau, 
and GATA3 were up-regulated in the presence of bone 
morphogenetic protein 4 (BMP4), demonstrating their 
capacity to differentiate into auditory neuron-like cells in 
vitro30. Rat BMSCs cultured in a medium containing glial 
cell-derived neurotrophic factor (GDNF), brain-derived 
neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) 
for 14 days were differentiated into neuronal progenitor 
cells which in turn can differentiate into neuronal cells, 
and therefore might be useful for the treatment of 
sensorineural hearing loss (SNHL)31. It has also been 
reported that hMSCs differentiation into an intermediate 
neural progenitor stage is essential to obtain inner ear 
sensory lineages. In a study conducted by Alonso et al., 
neuron-like cells were obtained from neural progenitors 
grown in serum-free medium containing EGF and retinoic 
acid and then hair cell-like cells and auditory cells were 
generated from neuron-like cells32. 
Hearing recovery after transplantation of MSCs 
Deafness animal models have been used to 
transplant MSCs differentiated into sensory neuron-
like cells27,33. Indeed a useful approach for inner 
ear supplementation with stem cells can be hMSCs 
systemic application34. For instance, the number of spiral 
ganglion neurons (SGNs) in guinea pig model is increased 
after transplantation of neural differentiated hMSCs 
resulting in mild hearing recovery after transplantation33.
The BMSCs have been fruitfully transplanted into 
young mice cochlea via the perilymphatic perfusion 
technique and further differentiated into fibrocyte-like (SLF-
like) cells35. The hearing recovery after transplantation of 
MSCs into the inner ear cells may be occurred through 
two mechanisms. First, MSCs transdifferentiation into 
SLF-like cells may lead to compensate for lost SLFs, 
and second, transplanted MSCs may stimulate the 
host SLFs regeneration. Both mechanisms contribute 
to functional recovery of damaged SLF network and 
thus, transplantation of MSCs into the inner ear of rats 
with damaged SLFs significantly accelerates hearing 
recovery36. The potential of neural-induced human MSCs 
(NI-hMSCs) to help replace the lost cochlear cells in 
hearing loss mammals has been investigated. Indeed, 
grafted NI-hMSCs migrate into the spiral ganglion 
where they expressed the neuron-specific marker, 
NeuN37. A study on transplantation of undifferentiated 
mouse BMSCs into normal and ouabain-treated 
gerbil cochleae and determination of their migratory 
patterns has demonstrated that survival of transplanted 
MSCs into the modiolus of the cochlea may result in 
regeneration of damaged SGNs38. In a similar study, rats 
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with transplanted MSCs in the lateral wall demonstrated 
a significantly higher hearing recovery comparing to 
negative controls suggesting that MSCs transplantation 
results in hearing recovery through the repair of injured 
cochlear fibrocytes39. Furthermore, bone marrow-derived 
cells may have the ability to attenuate cochlear injury 
by replacing or regenerating mesenchymal cells and 
fibrocytes in the inner ear40. These findings suggest that 
BMSCs can differentiate into neuronal progenitor cells 
and therefore may represent a promising biological 
element for treatment of inner ear disease, such as 
SNHL31. Furthermore, cells originating from bone marrow 
particularly those derived from hematopoietic stem cells 
(HSCs), seem to have the capibility to engraft into the 
inner ear41.
Recombinant BMSCs 
Upon transplantation, BMSCs expressing 
recombinant IL-4 have the ability to remediate the 
inflammatory injury in autoimmune inner ear diseases42. 
In an attempt to provide a regenerative therapy for 
deafness in 2014, Buddy and co-workers successfully 
forced hBMSCs to express essential genes in the otic 
lineages43. Additionally, BDNF gene-modified MSCs are 
known to have a protective effect on the spiral ganglion 
cells44. Another example is genetic manipulation for 
Atoh1 which is a master gene for the differentiation of 
the hair cells. Indeed administration of Atoh1 expression 
can be highly beneficial for hair cell development and 
regeneration45. The neurosensory progenitors from bone 
marrow can also be converted to sensory hair cells 
through overexpression of Atoh-146. Moreover it is known 
that BMSCs can be induced to differentiate into hair cells 
through a combination of growth factor stimulation and 
expression of the transcription factor Atoh-146. 
Activation of BMSCs homing for hearing recovery
In an attempt to determine the homing capacity 
of BMSCs, Tan and co-workers transplanted BMCs from 
green fluorescent protein (GFP) transgenic mice into 
the irradiated mice and then induced hearing injury by 
acoustic deafening. They observed GFP+ cell migration 
to the deafened cochlea particularly at the perilymphatic 
compartment walls, spiral ligament and limbus regions47. 
A new promising strategy for the activation of stem cell 
homing factors is induction of stem cell homing factors 
(SDF-1 and MCP-1) in the host cochlear tissue, and their 
receptors (CCR2 and CXCR4) in transplanted MSCs48. 
This knowledge suggests that activation of stem cell 
homing can be an effective strategy for hearing recovery.
Adipose tissue derived MSCs 
Adipose-derived stem cells (ASCs) can be isolated 
easily from blood vessels of adipose tissue49. These 
multipotent cells reside in the stromal vascular fraction 
and exhibit great plasticity and multilineage differentiation 
potential50. ASCs are capable to differentiate into all 
mesodermal lineages such as adipose tissue and other 
connective tissues (bone, cartilage, and muscles)51. 
However there are evidences that ASCs can be helpful 
in hearing repair. An original proof for developments of 
ASC-based treatments for deafness is that ASCs can 
migrate to the tissue damage location and express trophic 
factors52. Systemic infusion of ASC has been reported 
to significantly protect hair cells and improve hearing 
function in guinea pig with autoimmune hearing loss52. 
Additionally, the paracrine activity of hASC is 
known to help hearing restoration. The hASCs cause 
decrease in proliferation of antigen-specific Th1/Th17 
cells by inducing the production of anti-inflammatory 
cytokine interleukin-10 in splenocytes. They also induce 
the generation of antigen-specific CD4+ CD25+ Foxp3+ 
Treg cells with the capacity to suppress autoantigen-
specific T-cell responses53. In a study on guinea pig, the 
capability of ASCs to differentiate into neuron-like cells 
was investigated representing ASCs obtained from 
the neck as a good cell source for autologous cell-
based regenerative methods54. ASCs are able to migrate 
to the location of tissue damage and express trophic 
factors throughout intracochlear implantation in guinea 
pig model of acoustic trauma52. 
A strategy based on combination of total protein 
extract transfer from VOT-E36 otic epithelial cells and 
Atoh1 overexpression represents a novel method to 
convert ASCs into hair cell-like cells. Atoh1 overexpression 
successfully transforms VOT-E36 cells into hair cell-
like cells which further can attract contacts from spiral 
ganglion neurons in a co-culture medum55. The above 
mentioned evidences suggest that ASCs may be suitable 
tools to be used in regenerative medicine, because of 
their high plasticity and trophic features. Combined with 
conventional therapies, such as cochlear implantation, 
the feasibility of local ASCs delivery can contribute to 
future innovative biological strategies to enhance the 
endogenous reparative processes in the early stage of 
injury.
Umbilical Cord MSCs (UCMSCs) 
Abundance of umbilical cords, low immune rejection 
and nontumorigenic properties, have made UCMSCs to 
be considered an excellent source for cell transplantation 
therapies and regenerative medicine56. It is known that 
the expression of Atoh1 leads to induce the differentiation 
of hUCMSCs into cells that are morphologically and 
immunocytochemical similar to inner ear hair cells57. 
Interestingly, there are evidences that UCMSCs 
are beneficial even without genetic manipulation. For 
instance, intravenous transplantation of intact UCMSCs 
can itself improve hearing thresholds via relocation and 
increasing in the number of spiral ganglion neurons 
(SGNs)58. Furthermore, other findings indicate that the 
migration of transplanted human cord blood CD133+ 
hematopoietic stem cells (HSC) to the inner ear leads to 
the resumption of deafened cochlea of oto-injured mice59. 
The implanted cells are further integrated into the cochlea 
of the inner ear suggesting a possible strategy for 
rehabilitation of inner ear. In addition, the number of spiral 
ganglion cells and outer hair cells are increased and 
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according to auditory brainstem response (ABR) tests, 
the hearing level improved60. 
Olfactory stem cells (mesenchymal-like stem cells) 
The nasal olfactory stem cells from the human 
olfactory mucosa can be efficiently used for autologous 
stem cell-based therapies mainly due to their high 
abundance and easy accessibility 61. Olfactory stem cells 
have been successfully injected into the cochlea of mice 
with excellent outcomes. The transplantation of adult 
human olfactory mucosa-derived stem cells has been 
also found to help preserve auditory function during early-
onset progressive sensorineural hearing loss62. There are 
also evidences that the human mesenchymal-like stem 
cells derived from nasal tissue can repair spiral ganglion 
loss in experimentally injured cochlear of neonatal rats63. 
DISCUSSION
Due to highly promising nature of stem cells for 
regenerative medicine, intensive researches are being 
conducted to treat various diseases using embryonic, adult 
or induced pluripotent stem cells64. Cell based researches 
include a wide range of attempts such as treatments to 
aid nerve protection65,66 and regeneration or recovering 
cardiac tissue67. In this regard, various aspects of 
developmental biology and molecular signaling networks 
must be considered68,69. Multi differentiation potential of 
MSCs and their capability to migrate into acute injury 
location make these cells suitable candidate for gene and 
cell therapy70-74. MSCs have been demonstrated to be 
helpful in treating inner ear inflammatory damage because 
they exhibit multidirectional differentiation potential, 
immunosuppressive function and low immunogenicity75. 
Among MSCs, BMSCs have been widely studied and are 
comparably more practical58. Various studies indicate 
potential of BMSC to deliver therapeutic molecules and 
restore cochlear cells. BMSC transplantation could be 
utilized through three different strategies for inner ear 
treatment; restoration of missing cells, providing growth 
factors and delivering genes. Current findings on MSCs 
treatment efficacy in otorhinolaryngology are based on 
animal models. The true impact on clinical treatment 
will not be revealed until clinical trials confirm functional 
outcomes in human medicine. Two limitations of MSCs 
replacement is the process of MSCs relocation into the 
inner ear and the fact that stem cells do not spontaneously 
divide to replace damaged sensory cells. In spite of high 
plasticity, the capability of trans-differentiation along non-
mesodermal lineages is highly questionable. Particularly, 
possible neural trans-differentiation of MSCs, such as 
ASCs, is still being challenged76-78. Studies have confirmed 
the ability of the easily obtained and autologously 
available adult human stem cell to repair auditory neuron 
loss. However research should progress toward the 
establishment of cell-based therapies for certain forms of 
deafness63. In vitro studies have shown the differentiation 
of mouse MSCs into glutamatergic sensory neurons28 
and HC-like cells46,79. Since bone marrow transplants 
have been used by clinicians for decades, it would be 
more likely to move from animal trials using hMSCs, and 
hematopoietic stem cells toward clinical trials67. 
CONCLUSION
Stem cell therapy for sensorineural hearing aims to 
repair the hair cells and spiral ganglion cells to improve the 
auditory function. MSC transplantation for the treatment 
of hearing loss has opened up a new way of thinking. 
This review suggests that BMSCs are more capable to 
migrate and survive into the cochlear tissues which them 
suitable to be used in transplantation as a strategy for 
regenerating inner ear and treatment of SNHL.
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